Topics

Biogen Inc.  Company Profile

13:15 EDT 21st September 2019 | BioPortfolio


News Articles [494 Associated News Articles listed on BioPortfolio]

Skyhawk Therapeutics gibt Ausweitung des Kooperationsabkommens mit Biogen bekannt Biogen

- Skyhawk wird Kooperation mit Biogen ausweiten, um neue niedermolekulare RNA-Spleißmodifikatoren für Krankheits-Targets zu entwickeln - Biogen tätigt zusätzliche Vorabzahlung an Skyhawk, außerde...

Fujifilm acquires Biogen Hillerød facility for US$890 million

On 12 March 2019, Biogen announced that it had entered into an agreement with Fujifilm Corporation under which Fujifilm will acquire Biogen Manufacturing ApS from Biogen for up to US$890 million in ca...

Biogen Stock Crash: Opportunity or Concern?

Today, Biogen, one of the largest biotech stocks (IBB) lost 29 pct. Is this an opportunity to get in at low prices? Or is this just the start of something much bigger? Note that biogen is not part ...

Schwerer Rückschlag für Biogen - Aktie bricht ein

Einen schweren Rückschlag im Bereich Alzheimer-Forschung musste der US-Biotechkonzern Biogen heute melden. Biogen hat zusammen mit dem Forschungspartner Eisai die Forschungsstudien zum Medikamentka.....

wikifolio whispers p.m. zu Biogen Idec, Wirecard, Axel Springer ...

Biogen Idec 0.32% finelabels (FLB1899): Biogen Inc. übertrifft im zweiten Quartal mit einem Gewinn je Aktie von $9,15 die Analystenschätzungen von $7,53. Umsatz mit $3,6 Mrd. über den Erwartungen v...

Biogen vs. Celgene - welche Aktie ist der bessere Kauf?

Zu Beginn des Jahres haben Biogen (WKN: 789617) und Celgene (WKN: 881244) über ähnliche Marktkapitalisierungen verfügt. Das ist im Moment jedoch nicht der Fall. Im März gab Biogen bekannt, dass es...

Biogen to buy gene therapy co focused on rare eye disease

Biogen has agreed to buy British gene-therapy company Nightstar Therapeutics, accelerating Biogen's entry into the emerging growth area of eye diseases.

Biogen Inc.: Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

Nightstar acquisition further bolsters Biogen's pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programsCAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Tecfidera [biogen inc.]

These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for TECFIDERA.TECFIDERA (dimethyl fumarate) delayed-release capsule...

Tysabri [biogen inc.]

These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI.TYSABRI (natalizumab) injection, for intravenous useIniti...

Rituxan hycela [genentech, inc.]

These highlights do not include all the information needed to use RITUXAN HYCELA safely and effectively. See full prescribing information for RITUXAN HYCELA. RITUXAN HYCELA (rituximab and hyaluronidas...

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma.

Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (IC...

Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?

There is currently a movement to make economic models more transparent, with some arguing for completely open-source models. However, increasing model transparency raises several logistical challenges...

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 wh...

Safety and Tolerability of Repeat Courses of IM Alefacept

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experi...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort

DESIGN: exploratory, prospective, natural history, imaging cohort study BACKGROUND: Stroke causes a strong inflammatory response in the brain which is thought to contribute to permanent b...

Companies [31 Associated Companies listed on BioPortfolio]

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Inc.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hema...

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

More Information about "Biogen Inc. " on BioPortfolio

We have published hundreds of Biogen Inc.  news stories on BioPortfolio along with dozens of Biogen Inc.  Clinical Trials and PubMed Articles about Biogen Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Inc.  Companies in our database. You can also find out about relevant Biogen Inc.  Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record